These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 3306319

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Urinary inhibitory activity of calcium oxalate monohydrate crystal growth in stone-formers & non stone-formers.
    Sidhu H, Vaidyanathan S, Wangoo D, Rattan V, Thind SK, Nath R, Malakondaiah GC, Tandon SP.
    Indian J Med Res; 1987 Oct; 86():500-5. PubMed ID: 3443483
    [No Abstract] [Full Text] [Related]

  • 4. Urinary calcium oxalate crystal growth inhibitors.
    Worcester EM.
    J Am Soc Nephrol; 1994 Nov; 5(5 Suppl 1):S46-53. PubMed ID: 7873744
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Uronic-acid-rich protein: a new glycoprotein inhibiting the crystallization of calcium oxalate in vitro].
    Atmani F, Lacour B, Daudon M.
    Nephrologie; 1996 Nov; 17(3):157-62. PubMed ID: 9064564
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fibronectin as a potent inhibitor of calcium oxalate urolithiasis.
    Tsujihata M, Miyake O, Yoshimura K, Kakimoto KI, Takahara S, Okuyama A.
    J Urol; 2000 Nov; 164(5):1718-23. PubMed ID: 11025758
    [Abstract] [Full Text] [Related]

  • 9. [Inhibitory effect of CG-120 on the formation, growth and aggregation of calcium oxalate crystals in vitro].
    Suzuki K, Tsugawa R.
    Hinyokika Kiyo; 1988 Jun; 34(6):1073-6. PubMed ID: 3223452
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [The inhibitory effects of Takusha on the formation, growth and aggregation of calcium oxalate crystals in vitro].
    Kawamura K, Moriyama M, Nakajima C, Miyazawa K, Suzuki K, Tsugawa R.
    Hinyokika Kiyo; 1993 Aug; 39(8):695-700. PubMed ID: 8379469
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Inhibitory effect of oral administration of Takusya on calcium oxalate crystallization in human whole urine].
    Honda M, Yoshimura K, Miyake O, Yoshioka T, Okuyama A, Yamaguchi S, Utsunomiya M, Koide T, Sugiyama K.
    Hinyokika Kiyo; 1997 May; 43(5):333-7. PubMed ID: 9208316
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Uropontin in urinary calcium stone formation.
    Hoyer JR.
    Miner Electrolyte Metab; 1994 May; 20(6):385-92. PubMed ID: 7783701
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [A study of crystallization on urolithiasis in vitro].
    Miyazawa K, Suzuki K, Tsugawa R.
    Hinyokika Kiyo; 1991 Oct; 37(10):1091-6. PubMed ID: 1721765
    [Abstract] [Full Text] [Related]

  • 18. Concentration of a potent calcium oxalate monohydrate crystal growth inhibitor in the urine of normal persons and kidney stone patients by ELISA-based assay system employing monoclonal antibodies.
    Moghadam MF, Tandon C, Aggarwal S, Singla SK, Singh SK, Sharma SK, Varshney GC, Jethi RK.
    J Cell Biochem; 2003 Dec 15; 90(6):1261-75. PubMed ID: 14635198
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.